This predominance of TNBC studies seems paradoxical given the higher expression of LIV1 in HR+ tumors as compared to TN tumors, which clearly justifies clinical evaluation of ladiratuzumab vedotin in HR+/HER2 BC. This evidence concerns the gene ERBB2 and breast cancer.